New hope for lung cancer patients with brain tumors: targeted drug T-DXd enters trial
NCT ID NCT06250777
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug T-DXd (Enhertu) in 27 adults with advanced HER2-mutant lung cancer that has spread to the brain but is not causing symptoms. The main goal is to see how long the drug can keep brain tumors from growing. T-DXd is already approved for certain lung cancers, and this study focuses on patients with brain metastases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trastuzumab deruxtecan (T-DXd, Enhertu)
What this could lead to
If successful, this could provide a treatment option that controls both lung tumors and brain metastases in patients with HER2-mutant lung cancer.
What could go wrong
This is a small, early-phase trial with only 27 participants, so results may not apply to all patients. There is a risk of side effects like interstitial lung disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yonsei University Health system, Severance Hospital
Seoul, South Korea